Synthesis and in vitro antitumor activity of 4(3H)-quinazolinone derivatives bearing dithiocarbamate chains

Yaoxue Xuebao

Volumn 42, Issue 7, 2007, Pages 741-746

  Cao, Sheng Li ^a   Jiang, Yu Yang ^b   Feng, Yu Ping ^b   Liu, Shi Ying ^b   Gao, Hong He ^a   Zhang, Mei ^a   Wan, Rong ^b  

^a CAPITAL NORMAL UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

4(3H) quinazolinone; Antitumor activity; Dithiocarbamate

Indexed keywords

4 HYDROXYQUINAZOLINE; 4-HYDROXYQUINAZOLINE; ANTINEOPLASTIC AGENT; N,N' ETHYLENEBIS(DITHIOCARBAMIC ACID) DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ARTICLE; CELL STRAIN K 562; CHEMICAL STRUCTURE; CHEMISTRY; HELA CELL; HUMAN; IC 50; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; ETHYLENEBIS(DITHIOCARBAMATES); HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; MOLECULAR STRUCTURE; QUINAZOLINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548459355     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Curtin NJ, Hughes AN. Pemetrexed disodium, a novel antifolate with multiple targets [J]. Lancet Oncol, 2001,2:298-306.
2. Marsham PR, Hughes LR, Jackman AL, et al. Quinazoline antifolate thymidylate synthase inhibitors; heterocyclic benzoyl ring modifications [J]. J Med Chem, 1991, 34:1594-1605.
3. Cunningham D, Zalcberg J, Maroun J, et al. Efficacy, tolerability and management of raltitrexed monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials [J]. Eur J Cancer, 2002,38:478-486.
4. Webber S, Bartlett CA, Boritzki TJ, et al. AG337, a novel lipophilic thymidylate synthase inhibitors; in vitro and in vivo preclinical studies [J]. Cancer Chemother Pharmacol, 1996,37-517.
5. Marsham PR, Wardleworth JM, Boyle FT, et al. Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors [J]. J Med Chem, 1999,42:3809-3820.
6. Creaven PJ, Pendyala L, Meropol NJ, et al. Initial clinical trial and pharmacokinetics of Thymitaq™ (AG337) by 10-day continuous infusion in patients with advanced solid tumors [J]. Cancer Chemother Pharmacol, 1998,41:167-170.
7. Chu E, Callender MA, Farrell MP, et al. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside [J]. Cancer Chemother Pharmacol, 2003,52:S80-S89.
8. Mehta RG, Liu J, Constantinou A, et al. Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage [J]. Carcinogenesis, 1995,16:399-404.
9. Guo BG, Ge ZM, Cheng TM, et al. Synthesis and antitumor activities of 1, 4-bis [ 3-(aminodithiocarboxy) propionyl] piperazine derivatives [J]. Acta Pharm Sin, 2001,36:185-187.
10. Gtlzel O, Salman A, Synthesis, antimycobacterial and antitumor activities of new (1, 1-dioxido-3-oxo-1, 2-benzisothiazol-2 (3H)-yl) methyl N, N-disubstituted dithiocarbamate/O-alkyldithiocarbonate derivatives [J]. Bioorg Med Chem, 2006,14:7804-7815.
11. Cao SL, Feng YP, Jiang YY, et al. Synthesis and in vitro antitumor activity of 4 (3H)-quinazolinone derivatives with dithiocarbamate side chains [J]. Bioorg Med Chem Lett, 2005,15:1915-1917.
12. Cao SL, Ma XQ. Synthesis of 6-bromomethyl-2-methyl-4-oxoquinazoline [J]. Chem Reagents, 2004, 26; 27-28.